Remote Electrical Neuromodulation for the Acute Treatment of Chronic Migraine (2007)

• DOI: 10.1212/wnl.96.15_supplement.2007
• Publication Date: 2023-12-07T05:55:31Z
• Authors: Brian Grosberg; Tamar Lin; Maya Vizel; Jack Schim
• Keywords: Neuromodulation; Chronic Migraine; Migraine Disorders

Objective: This study aimed to assess the safety and effectiveness of remote electrical neuromodulation (REN) in people with chronic migraine. Background: REN (Nerivio®, Theranica Bio-Electronics LTD., Israel) is an acute treatment for Results from several studies patients episodic migraine suggest that effective safe In addition, a recent pilot provided initial support migraine, but additional data needed establish this population. Design/Methods: open-label, single-arm study, treated their headaches device 4 weeks following 4-week run-in phase. Pain levels, associated symptoms functional disability were recorded at initiation, 2 hours after 24 treatment. Results: One hundred twenty-six subjects enrolled into which 91 had evaluable REN. relief pain disappearance achieved by 59.3% (54/91) 20.9% (19/91) subjects, respectively. Sustained was observed 73.3% (33/45) subjects. The findings show has favorable effect on nausea, photophobia, phonophobia, improves ability. device-related adverse event reported. Conclusions: treatments results symptoms, thus, offering drug-free option Disclosure: Dr. Grosberg received personal compensation range $500-$4,999 serving Scientific Advisory or Data Safety Monitoring board Amgen. $5,000-$9,999 Lundbeck . Theranica. Allergan. Speakers Bureau Biohaven. stock ownership interest institution research Electrocore. Reddy. Migraine Research Foundation. publishing royalties publication relating health care. Tamar Lin as employee Bio-Electronics. Maya Vizel Schim $10,000-$49,999 Consultant Aeon, Allergan, Amgen, Biohaven, electroCore, Impel, Lilly, Lundbeck, Novartis, Promius, Revance, Teva, Upsher-Smith. $100,000-$499,999 Theranica,